Related Experiment Videos
Immunoadsorption in dilated cardiomyopathy.
1Department of Internal Medicine B, Ernst-Moritz-Arndt University Greifswald, Germany. felix@uni-greifswald.de
Ernst Schering Research Foundation Workshop
|December 7, 2005
Summary
Dilated cardiomyopathy (DCM) is linked to cardiac autoantibodies. Removing these IgG antibodies via immunoadsorption therapy improves heart function in DCM patients, suggesting a key immune system role.
Area of Science:
- Cardiology
- Immunology
- Internal Medicine
Background:
- Dilated cardiomyopathy (DCM) involves progressive heart muscle dysfunction and chamber enlargement.
- Immune system abnormalities, including autoantibodies targeting cardiac structures, are observed in DCM patients.
- The precise role of cardiac autoantibodies in DCM pathogenesis remains under investigation.
Purpose of the Study:
- To investigate the functional significance of cardiac autoantibodies in dilated cardiomyopathy.
- To assess the impact of removing cardiac autoantibodies on cardiac performance in DCM patients.
Main Methods:
- Analysis of cardiac autoantibodies (IgG fraction) in DCM patients.
- In vitro studies to evaluate the effect of specific antibodies on cardiac function.
- Clinical studies utilizing immunoadsorption therapy to eliminate cardiac antibodies.
Main Results:
- In vitro data suggest certain cardiac antibodies negatively impact cardiac performance.
- Evidence indicates cardiac antibodies can directly induce DCM.
- Immunoadsorption therapy successfully removed IgG antibodies in DCM patients.
- Clinical studies demonstrated improved cardiac function following antibody removal.
Conclusions:
- Activation of the humoral immune system, specifically cardiac autoantibodies, plays a functional role in dilated cardiomyopathy.
- Immunoadsorption therapy is a promising treatment for DCM by targeting antibody-mediated mechanisms.